Abstract

BackgroundMalaria rapid diagnostic tests (RDTs) play a critical role in malaria case management, and assurance of quality is a key factor to promote good adherence to test results. Since 2007, the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) have coordinated a Malaria RDT Evaluation Programme, comprising a pre-purchase performance evaluation (product testing, PT) and a pre-distribution quality control of lots (lot testing, LT), the former being the basis of WHO recommendations for RDT procurement. Comprehensive information on malaria RDTs sold worldwide based on manufacturers’ data and linked to independent performance data is currently not available, and detailed knowledge of procurement practices remains limited.MethodsThe use of the PT/LT Programme results as well as procurement and lot verification practices were assessed through a large-scale survey, gathering product-specific RDT sales and procurement data (2011–14 period) from a total of 32 manufacturers, 12 procurers and 68 National Malaria Control Programmes (NMCPs).ResultsManufacturers’ reports showed that RDT sales had more than doubled over the four years, and confirmed a trend towards increased compliance with the WHO procurement criteria (from 83% in 2011 to 93% in 2014). Country-level reports indicated that 74% of NMCPs procured only ‘WHO-compliant’ RDT products, although procurers’ transactions datasets revealed a surprisingly frequent overlap of different products and even product types (e.g., Plasmodium falciparum-only and Plasmodium-pan) in the same year and country (60 and 46% of countries, respectively). Importantly, the proportion of ‘non-complying’ (i.e., PT low scored or not evaluated) products was found to be higher in the private health care sector than in the public sector (32% vs 5%), and increasing over time (from 22% of private sector sales in 2011 to 39% in 2014). An estimated 70% of the RDT market was covered by the LT programme. The opinion about the PT/LT Programmes was positive overall, and quality of RDTs as per the PT Programme was rated as the number one procurement criteria.ConclusionsThis survey provided in-depth information on RDT sales and procurement dynamics, including the largely unstudied private sector, and demonstrated how the WHO–FIND Programme has positively influenced procurement practices in the public sector.

Highlights

  • Malaria rapid diagnostic tests (RDTs) play a critical role in malaria case management, and assurance of quality is a key factor to promote good adherence to test results

  • The lot testing (LT) programme evaluates samples of individual product batches before distribution and use, thereby stimulating manufacturers to maintain RDTs at a consistently high-quality standard, and increasing the confidence of RDT procurers and users. This LT service can be requested by any entity that would like to confirm the quality of RDT lots, i.e. the RDT manufacturers or various types of RDT procurers such as Ministries of Health (MoH), National Malaria Control Programmes (NMCP), non-governmental organizations (NGO), procurement agencies and other international organizations (IO); RDT procurers can ask the RDT manufacturers to handle the lot testing request as part of the procurement contract

  • More than half of the NMCP/MoHs participating in the survey belonged to the World Health Organization (WHO) Regional Office for Africa (AFRO) region (38/68, 56%)

Read more

Summary

Introduction

Malaria rapid diagnostic tests (RDTs) play a critical role in malaria case management, and assurance of quality is a key factor to promote good adherence to test results. Since 2007, the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) have coordinated a Malaria RDT Evaluation Programme, comprising a pre-purchase performance evaluation (product testing, PT) and a pre-distribution quality control of lots (lot testing, LT), the former being the basis of WHO recommendations for RDT procurement. The PT programme compares commercially available RDTs and publishes comparative data on performance, ease of use and stability, with 247 products having been evaluated as of 2015 [5,6,7,8,9,10,11] This programme currently constitutes the basis of WHO procurement recommendations [12], and forms the laboratory evaluation component of the WHO Prequalification of Diagnostics Programme (WHO PQ). The lot testing (LT) programme evaluates samples of individual product batches (or ‘lots’) before distribution and use, thereby stimulating manufacturers to maintain RDTs at a consistently high-quality standard, and increasing the confidence of RDT procurers and users. Since 2007, more than 4000 malaria RDT lots have been tested at two WHO–FIND-recognized Lot Testing laboratories, based in The Philippines and Cambodia [13]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call